Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | GAA | P10253 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.97 |
| ▸ | HPGD | P15428 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.97 |
| ▸ | GLA | P06280 | 4/20 | 0.80 |
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.55 |
| ▸ | CDK2 | P24941 | 3/20 | 0.55 |
| ▸ | CDK4 | P11802 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3641493 | 1.00 | KDM4E (1.00) | KDM4EGAAHSD17B10KMT2AMAPT | |
| SCHEMBL3778613 | 0.99 | KDM4E (1.00) | KDM4EGAAHSD17B10KMT2AMAPT | |
| SCHEMBL3640035 | 0.99 | KDM4E (1.00) | KDM4EGAAHSD17B10KMT2AMAPT | |
| SCHEMBL3640032 | 0.99 | KDM4E (1.00) | KDM4EGAAHSD17B10KMT2AMAPT | |
| SCHEMBL3643100 | 0.92 | KDM4E (0.86) | KDM4EGAAHSD17B10KMT2AMAPT | |
| SCHEMBL3643098 | 0.92 | KDM4E (0.86) | KDM4EGAAHSD17B10KMT2AMAPT | |
| SCHEMBL3639044 | 0.91 | KDM4E (0.84) | KDM4EGAAHSD17B10KMT2AMAPT | |
| SCHEMBL3639040 | 0.91 | KDM4E (0.84) | KDM4EGAAHSD17B10KMT2AMAPT | |
| SCHEMBL3772212 | 0.91 | KDM4E (0.84) | KDM4EGAAHSD17B10KMT2AMAPT | |
| SCHEMBL3772215 | 0.91 | KDM4E (0.84) | KDM4EGAAHSD17B10KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117883579-B | Application of nuclear transport receptor importin-beta serving as acting target in preparation of medicine for treating radioactive liver fibrosis | 南方医科大学南方医院 | 2025-03-14 | — | — | CN | claimed |
| US-20240294986-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2024-09-05 | — | — | US | claimed |
| EP-4355423-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | Indiana University Research and Technology Corporation (US) | 2024-04-24 | — | — | EP | claimed |
| CN-117883579-A | Application of nuclear transport receptor importin-beta as acting target in preparation of medicine for treating radioactive liver fibrosis | 南方医科大学南方医院 | 2024-04-16 | — | — | CN | claimed |
| US-20220403469-A1 | Precision Medicine for Schizophrenia and Psychotic Disorders: Objective Assessment, Risk Prediction, Pharmacogenomics, and Repurposed Drugs | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-12-22 | — | — | US | claimed |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-08-11 | — | — | US | claimed |
| US-20260102391-A1 | INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS | LORICO AURELIO (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260097053-A1 | COMPOSITIONS AND METHODS FOR MODULATING CHOLESTEROL EFFLUX | CLEVELAND STATE UNIV (US) | 2026-04-09 | — | — | US | disclosed |
| US-12569483-B2 | Methods for objective assessment of memory, early detection of risk for Alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260028426-A1 | NUCLEAR LOCALIZATION SIGNALS, COMPOSITIONS FORMED THEREFROM, AND METHODS OF USE THEREOF FOR DELIVERY OF CARGO TO THE NUCLEUS | UNIV YALE (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4684007-A1 | IMPROVED YIELD OF PARAMYXOVIRUS-LIKE PARTICLES THROUGH USE OF ALTERED VIRAL MATRIX PROTEINS | The Penn State Research Foundation (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12527789-B2 | Inhibition of a tripartite VOR protein complex in multicellular organisms | LORICO, Aurelio (US) | 2026-01-20 | — | — | US | disclosed |
| CN-120346210-A | Use of Importazole in obesity | 西南医科大学 | 2025-07-22 | — | — | CN | disclosed |
| EP-3193863-B1 | SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | UNIV CAPE TOWN (ZA) | 2022-07-13 | — | — | EP | disclosed |
| US-20220211700-A1 | Methods for Objective Assessment of Memory, Early Detection of Risk for Alzheimer's Disease, Matching Individuals With Treatments, Monitoring Response to Treatment, and New Methods of Use for Drugs | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-07 | — | — | US | disclosed |
| WO-2022138936-A1 | MYELIN SHEATH REPAIR AGENT | 国立研究開発法人国立精神・神経医療研究センター | 2022-06-30 | — | — | WO | disclosed |
| US-20220193056-A1 | COMPOSITIONS AND METHODS OF TREATING PIK3CA HELICAL DOMAIN MUTANT CANCERS | CASE WESTERN RESERVE UNIVERSITY | 2022-06-23 | — | — | US | disclosed |
| US-11339375-B2 | Paramyxovirus virus-like particles as protein delivery vehicles | THE PENN STATE RESEARCH FOUNDATION (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220081412-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-03-17 | — | — | US | disclosed |
| WO-2022049562-A1 | USE OF TRIAZOLE ANALOGUES FOR INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS | Technische Universität Dresden (DE) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097053-A1 | COMPOSITIONS AND METHODS FOR MODULATING CHOLESTEROL EFFLUX | NPC1L1, PIK3R5, LDLR | KDM4E 2807/4885GAA 2661/4885HSD17B10 2631/4885 |
| US-20260028426-A1 | NUCLEAR LOCALIZATION SIGNALS, COMPOSITIONS FORMED THEREFROM, AND METHODS OF USE THEREOF FOR DELIVERY OF CARGO TO THE NUCLEUS | PHAX, NXF1, KPNA2 | KDM4E 4184/4885GAA 1607/4885HSD17B10 4246/4885 |
| US-20220081412-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | HMGB3, HCCS, ACACA | KDM4E 2186/4885GAA 3688/4885HSD17B10 624/4885 |
| US-12527789-B2 | Inhibition of a tripartite VOR protein complex in multicellular organisms | VAPB, VAPA, OSBPL3 | KDM4E 4104/4885GAA 3015/4885HSD17B10 4595/4885 |
| US-12569483-B2 | Methods for objective assessment of memory, early detection of risk for Alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs | PSMB3, THRB, GRIN2B | KDM4E 3825/4885GAA 816/4885HSD17B10 1277/4885 |
| US-20260102391-A1 | INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS | VAPB, VAPA, RABL3 | KDM4E 4383/4885GAA 2270/4885HSD17B10 4789/4885 |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | GLA, LIMS1, GLB1 | KDM4E 3210/4885GAA 634/4885HSD17B10 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.